Published in Adv Urol on June 18, 2012
Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther (2013) 0.96
Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment? World J Biol Chem (2015) 0.94
Gene microarray analysis of the lncRNA expression profile in human urothelial carcinoma of the bladder. Int J Clin Exp Med (2014) 0.85
Genetic and Epigenetic Alterations in Bladder Cancer. Int Neurourol J (2016) 0.83
Assessment of DNA damage and telomerase activity in exfoliated urinary cells as sensitive and noninvasive biomarkers for early diagnosis of bladder cancer in ex-workers of a rubber tyres industry. Biomed Res Int (2014) 0.75
Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma. Oncotarget (2017) 0.75
Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. Indian J Urol (2015) 0.75
Epigenetic silencing of the MUPCDH gene as a possible prognostic biomarker for cyst growth in ADPKD. Sci Rep (2015) 0.75
Urinary tumor markers could predict survival in bladder carcinoma. Indian J Clin Biochem (2012) 0.75
Extracellular Nucleic Acids in Urine: Sources, Structure, Diagnostic Potential. Acta Naturae (2015) 0.75
Molecular signatures in urologic tumors. Int J Mol Sci (2013) 0.75
Biomarkers for precision medicine in bladder cancer. Int J Clin Oncol (2016) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell (1992) 27.80
Epigenetics in cancer. N Engl J Med (2008) 17.36
Role for DNA methylation in genomic imprinting. Nature (1993) 12.65
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 8.78
Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet (2009) 7.07
DNA methylation in cancer: too much, but also too little. Oncogene (2002) 6.96
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Chromosomal instability and tumors promoted by DNA hypomethylation. Science (2003) 6.02
Identification of a nuclear protein matrix. Biochem Biophys Res Commun (1974) 5.41
The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics (2003) 4.99
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol (2011) 4.25
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol (2005) 2.45
Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res (2005) 2.19
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res (2007) 1.77
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res (2006) 1.73
Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology (2006) 1.72
Aging, DNA methylation and cancer. Crit Rev Oncol Hematol (1999) 1.70
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res (2006) 1.65
Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res (2010) 1.62
DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet Cell Genet (2000) 1.62
Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess (2010) 1.62
Altered DNA methylation and genome instability: a new pathway to cancer? Proc Natl Acad Sci U S A (1997) 1.60
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol (2005) 1.58
Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst (1989) 1.55
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47
Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res (2011) 1.46
Urinary cytology in era of fluorescence endoscopy: redefining the role of an established method with a new reference standard. Urology (2010) 1.42
Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis (2007) 1.40
Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res (2002) 1.36
Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol (2007) 1.36
Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest (2004) 1.35
RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res (2005) 1.32
Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res (2007) 1.32
Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.30
Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer (2003) 1.24
Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res (2001) 1.23
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res (2004) 1.22
Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev (2011) 1.19
Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS One (2012) 1.19
Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer (2005) 1.18
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer (2010) 1.13
Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer (2007) 1.12
Tobacco and bladder cancer in males: increased risk for inhalers and smokers of black tobacco. Int J Cancer (1989) 1.10
The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res (2002) 1.10
Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol (1990) 1.08
Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol (2007) 1.06
The nuclear matrix: defining structural and functional roles. Crit Rev Eukaryot Gene Expr (1991) 1.05
Transcriptional regulation of the human LINE-1 retrotransposon L1.2B. Mol Genet Genomics (2003) 1.04
CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer. Int J Oncol (2009) 1.04
Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol (2001) 1.02
Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res (2004) 1.02
Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics (2011) 1.01
Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol (2009) 1.00
A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int (2011) 1.00
Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene (2006) 0.99
Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol (2012) 0.98
Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer (2006) 0.97
Urine-based assays for the detection of bladder cancer. Biomark Med (2009) 0.95
Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology (2008) 0.93
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol (2007) 0.92
Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem (2008) 0.91
Promoter analysis of epigenetically controlled genes in bladder cancer. Genes Chromosomes Cancer (2008) 0.89
Identification of PMF1 methylation in association with bladder cancer progression. Clin Cancer Res (2008) 0.88
BAMBI gene is epigenetically silenced in subset of high-grade bladder cancer. Int J Cancer (2009) 0.88
Discovery of myopodin methylation in bladder cancer. J Pathol (2008) 0.86
Concerning the role of X-inactivation and DNA methylation in fragile X syndrome. Am J Med Genet (1992) 0.84
Voided urinary cytology in bladder cancer: is it time to review the indications? Urology (2007) 0.84
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol (1996) 0.84
Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol J (2008) 0.84
Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer. Biomarkers (2010) 0.82